QNCX – quince therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential [Seeking Alpha]
Quince Therapeutics (NASDAQ:QNCX) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Quince Therapeutics (NASDAQ:QNCX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Quince Therapeutics (NASDAQ:QNCX) had its price target raised by analysts at D. Boral Capital from $4.00 to $5.00. They now have a "buy" rating on the stock.
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
Form 144 Quince Therapeutics, Filed by: Benatti Luca
Form 4 Quince Therapeutics, For: Dec 26 Filed by: Benatti Luca
Form 4 Quince Therapeutics, For: Oct 23 Filed by: Benatti Luca
Form 4 Quince Therapeutics, For: Dec 10 Filed by: Thye Dirk
Form 4 Quince Therapeutics, For: Dec 05 Filed by: Hannah Brendan
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.